## Edgar Filing: PDL BIOPHARMA, INC. - Form 4

PDL BIOPHARM	IA, INC.										
Form 4											
May 30, 2008									OMB APPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									3235-0287		
Check this box		vv a	ishington,	D.C. 20	547		Expires:	January 31,			
if no longer subject to Section 16. Form 4 or	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								Estimated average burden hours per response 0.5		
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940											
(Print or Type Respon	nses)										
1. Name and Address of Reporting Person <u>*</u> KLEIN JOSEPH III			2. Issuer Name <b>and</b> Ticker or Trading Symbol PDL BIOPHARMA, INC. [PDL]				5. Relationship of Reporting Person(s) to Issuer				
(Last) (	Middle)		of Earliest Ti		. []	(Check all applicable)					
				Day/Year) 2008	ansaction		X_ Director 10% Owner Officer (give titleOther (specify below) below)				
(	4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting						
REDWOOD CIT	Y, CA 9406	03					Person		1 8		
		(Zip)		le I - Non-I	Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned		
	nsaction Date th/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transaction Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Report on	a separate line	for each cl	ass of sec	urities benef	icially own	ned directly of	or indirectly				
rechnicer, report on	a separate me				Perso inform requir	ns who rest nation cont ed to respo ys a curren	pond to the colle ained in this form and unless the for ntly valid OMB co	i are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	iorDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

# Edgar Filing: PDL BIOPHARMA, INC. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (A or Disposed (D) (Instr. 3, 4, and 5)	d of			
				Code V	(A)	(D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 9.79	05/28/2008		A	2,500	<u>(1)</u>	05/28/2015	Common Stock	2,500
Stock Option (Right to Biy) (Common Stock)	\$ 9.79	05/28/2008		A	1,500	<u>(2)</u>	05/28/2015	Common Stock	1,500
Stock Option (Right to Buy) (Common Stock)	\$ 9.79	05/28/2008		A	667	<u>(3)</u>	05/28/2015	Common Stock	667
Stock Option (Right to Buy) (Commo Stock)	\$ 9.79	05/28/2008		A	1,000	<u>(4)</u>	05/28/2015	Common Stock	1,000
Stock Option (Right to Buy) (Common Stock)	\$ 9.79	05/28/2008		Α	4,583	<u>(5)</u>	05/28/2015	Common Stock	4,583
Stock Option (Right to Buy) (Common Stock)	\$ 9.79	05/28/2008		A	13,750	<u>(6)</u>	05/28/2015	Common Stock	13,750

# **Reporting Owners**

**Reporting Owner Name / Address** 

Relationships

### Signatures

#### /s/ Francis Sarena by Francis Sarena, Attorney-In-Fact for Joseph Klein III

<u>\*\*</u>Signature of Reporting Person

Х

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option will vest with respect to approximately 208 shares on June 28, 2008 and with respect to approximately 208 of the shares monthly thereafter.
- (2) This option will vest with respect to approximately 125 shares on June 28, 2008 and with respect to approximately 125 of the shares monthly thereafter.
- (3) This option will vest with respect to approximately 83 shares on October 28, 2008 and with respect to approximately 83 of the shares monthly thereafter.
- (4) This option will vest with respect to approximately 83 shares on June 28, 2008 and with respect to approximately 83 of the shares monthly thereafter.
- (5) This option will vest with respect to approximately 417 shares on August 28, 2008 and with respect to approximately 417 of the shares monthly thereafter.
- (6) This option will vest with respect to 1,250 shares on August 28, 2008 and with respect to 1,250 of the shares monthly thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

#### Edgar Filing: PDL BIOPHARMA, INC. - Form 4

Director 10% Owner Officer Other

KLEIN JOSEPH III C/O PDL BIOPHARMA, INC. 1400 SEAPORT BLVD REDWOOD CITY, CA 94063

#### 05/30/2008

Date